None

None

participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degree celsius (c) (100.4 degree fahrenheit [f]) within 24 hours prior to the planned study vaccination; randomization at a later date is permitted at the discretion of the investigator. please notify the sponsor (or medical monitor) of this decision participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine participant received treatment with immunoglobulins (ig) in the 3 months or exogenous blood products (autologous blood transfusions are not exclusionary) in the 4 months before the planned administration of the study vaccine or has any plans to receive such treatment during the study participant has a known history of confirmed severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection participant has a history of heparin-induced thrombocytopenia or thrombosis in combination with thrombocytopenia participant has a history of acute polyneuropathy (example. guillain-barre syndrome) history of capillary leak syndrome

participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degree celsius (c) (100.4 degree fahrenheit [f]) within 24 hours prior to the planned study vaccination; randomization at a later date is permitted at the discretion of the investigator. please notify the sponsor (or medical monitor) of this decision participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine participant received treatment with immunoglobulins (ig) in the 3 months or exogenous blood products (autologous blood transfusions are not exclusionary) in the 4 months before the planned administration of the study vaccine or has any plans to receive such treatment during the study participant has a known history of confirmed severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection participant has a history of heparin-induced thrombocytopenia or thrombosis in combination with thrombocytopenia participant has a history of acute polyneuropathy (example. guillain-barre syndrome) history of capillary leak syndrome